Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06097728
Title	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Acronym	eVOLVE-Meso
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	malignant pleural mesothelioma
Therapies	Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + MEDI5752 + Pemetrexed Disodium Ipilimumab + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| BEL \| AUS